Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 9/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.38 |
| ▸ | RET | P07949 | 4/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.38 |
| ▸ | PRKACA | P17612 | 3/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.38 |
| ▸ | CLK2 | P49760 | 3/20 | 0.38 |
| ▸ | GSK3A | P49840 | 3/20 | 0.38 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.38 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20910637 | 0.81 | KDR (0.33) | LIMK1CDK5RETDAPK3MAP4K4 | |
| SCHEMBL13471031 | 0.77 | PDE5A (0.31) | PDE5ACDK2 | |
| SCHEMBL15343944 | 0.76 | LIMK1 (0.41) | LIMK1CDK5RETDAPK3MAP4K4 | |
| SCHEMBL15340424 | 0.75 | NCF1 (0.40) | — | |
| SCHEMBL12261327 | 0.72 | LIMK1 (0.41) | LIMK1CDK5RETDAPK3MAP4K4 | |
| SCHEMBL22509671 | 0.71 | PI4KA (0.39) | LIMK1CDK5RETDAPK3MAP4K4 | |
| SCHEMBL19402873 | 0.71 | LIMK1 (0.38) | LIMK1CDK5RETDAPK3MAP4K4 | |
| SCHEMBL22509858 | 0.71 | PDE5A (0.39) | LIMK1CDK5RETDAPK3MAP4K4 | |
| SCHEMBL18699944 | 0.70 | — | — | |
| SCHEMBL22521606 | 0.69 | ADORA2A (0.39) | LIMK1CDK5RETDAPK3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | ALIGOS THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | IDENIX PHARMACEUTICALS LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | IDENIX PHARMACEUTICALS LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170275322-A1 | METHODS FOR THE PREPARATION OF DIASTEREOMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | MEDIVIR AB (SE) | 2017-09-28 | — | — | US | disclosed |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-9090642-B2 | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20130281686-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281686-A1 | METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | PAICS, DPYD, PNP | LIMK1 4647/4885CDK5 1261/4885RET 2418/4885 |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | RNMT, NUDT1, NTPCR | LIMK1 2168/4885CDK5 2893/4885RET 2886/4885 |
| US-20170275322-A1 | METHODS FOR THE PREPARATION OF DIASTEREOMERICALLY PURE PHOSPHORAMIDATE PRODRUGS | PNP, PAICS, NUDT1 | LIMK1 4595/4885CDK5 681/4885RET 2229/4885 |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | STING1, CGAS, IRF3 | LIMK1 3794/4885CDK5 4368/4885RET 4101/4885 |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | LIMK1 3794/4885CDK5 4368/4885RET 4101/4885 |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | RNMT, NUDT1, NTPCR | LIMK1 2168/4885CDK5 2893/4885RET 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.